Compare FCBC & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCBC | MGTX |
|---|---|---|
| Founded | 1874 | 2015 |
| Country | United States | United States |
| Employees | 610 | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 851.3M | 909.1M |
| IPO Year | 1996 | 2018 |
| Metric | FCBC | MGTX |
|---|---|---|
| Price | $45.12 | $13.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $24.57 |
| AVG Volume (30 Days) | 84.1K | ★ 1.0M |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | ★ 5.26% | N/A |
| EPS Growth | N/A | ★ 33.02 |
| EPS | ★ 0.63 | N/A |
| Revenue | N/A | ★ $81,391,000.00 |
| Revenue This Year | $12.28 | $141.38 |
| Revenue Next Year | $2.55 | N/A |
| P/E Ratio | $71.62 | ★ N/A |
| Revenue Growth | N/A | ★ 144.57 |
| 52 Week Low | $31.21 | $6.62 |
| 52 Week High | $45.84 | $13.94 |
| Indicator | FCBC | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 59.45 | 74.69 |
| Support Level | $41.04 | $7.10 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.09 | 0.74 |
| MACD | 0.13 | 0.32 |
| Stochastic Oscillator | 79.78 | 99.55 |
First Community Bankshares Inc is a financial holding company that provides commercial banking products and services. The company is engaged in providing demand deposit accounts, savings, and money market accounts, certificates of deposits; commercial, consumer, and real estate mortgage loans, and lines of credit; various credit card, debit card, and automated teller machine card services; corporate and personal trust services; investment management services and life, health, and property and casualty insurance products. The company's revenue is mainly derived from interest, fees, and commissions.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.